| |
| |
|
| Insider
Information: |
Fridriksdottir Hafrun |
| Relationship: |
Executive VP, Global R&D |
| City: |
Parsippany |
| State: |
NJ |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
8,301 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$1,353,695 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
8,301 |
|
|
| Total
Value |
$1,353,695 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
2
|
|
Stock
price went up :
|
0
|
1
|
| Stock
price went down : |
0
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
 4.3%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Allergan plc |
AGN |
SVP, GLOBAL R&D |
2014-05-09 |
6,914 |
2013-10-01 |
0 |
Premium* |
|
|
Teva Pharmaceutical Industries L... |
TEVA |
Executive VP, Global R&D |
2022-05-17 |
1,387 |
2018-03-04 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2022-05-17 |
4 |
S |
$8.22 |
$1,068,067 |
D/D |
(130,000) |
1,387 |
0 |
% |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2022-03-07 |
4 |
AS |
$7.37 |
$65,866 |
D/D |
(8,941) |
126,087 |
0 |
% |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2022-03-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
23,764 |
135,028 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2022-03-04 |
4 |
AS |
$7.48 |
$184,354 |
D/D |
(24,638) |
111,264 |
0 |
% |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2022-03-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
70,393 |
117,882 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2022-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
21,682 |
73,099 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2022-02-28 |
4 |
AS |
$8.14 |
$61,799 |
D/D |
(7,590) |
65,509 |
0 |
% |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2022-02-09 |
4 |
AS |
$9.06 |
$55,412 |
D/D |
(6,116) |
51,417 |
0 |
% |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2022-02-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,121 |
57,533 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2021-08-10 |
4 |
S |
$9.95 |
$506,021 |
D/D |
(50,860) |
41,412 |
0 |
% |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2021-05-11 |
4 |
AS |
$10.22 |
$194,830 |
D/D |
(19,066) |
92,272 |
0 |
% |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2021-05-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
37,884 |
111,338 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2021-03-04 |
4 |
AS |
$10.57 |
$100,536 |
D/D |
(9,515) |
73,454 |
0 |
% |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2021-03-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
18,905 |
82,969 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2021-03-02 |
4 |
AS |
$10.82 |
$540,890 |
D/D |
(50,000) |
64,064 |
0 |
% |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2021-03-01 |
4 |
AS |
$10.83 |
$118,186 |
D/D |
(10,912) |
114,064 |
0 |
% |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2021-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
21,682 |
124,976 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2021-02-16 |
4 |
AS |
$11.12 |
$23,336 |
D/D |
(2,098) |
103,294 |
0 |
% |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2021-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,355 |
105,392 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2021-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
67,852 |
129,533 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2021-02-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,120 |
61,681 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2021-02-09 |
4 |
AS |
$12.69 |
$374,437 |
D/D |
(29,496) |
100,037 |
0 |
% |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2020-03-17 |
4 |
AS |
$7.16 |
$3,682 |
D/D |
(514) |
45,561 |
0 |
% |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2020-03-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,014 |
46,075 |
0 |
- |
|
| TEVA |
Teva Pharmaceutical Indus... |
Executive VP, Global R&D |
• – – |
2020-02-14 |
4 |
AS |
$12.14 |
$139,295 |
D/D |
(11,472) |
45,061 |
0 |
% |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
